Pulmonary Arterial Hypertension Worsened by Bosutinib in Patient With Previous Dasatinib Treatment

Parthvi, Rukma; Gibbons, William

doi:10.1097/mjt.0000000000001156

American Journal of Therapeutics

2020

DOI: 10.1097/mjt.0000000000001156

|View full text |Cite

Pulmonary Arterial Hypertension Worsened by Bosutinib in Patient With Previous Dasatinib Treatment

Rukma Parthvi

William Gibbons

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 14 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia

Lipton,

Brümmendorf,

Sweet

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

Bosutinib is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia (CML), and for patients with Ph + chronic phase, accelerated phase, or blast phase CML resistant or intolerant to prior therapy. As is the case for all TKIs approved for treatment of CML, bosutinib is associated with adverse events (AEs) that require appropriate management to ensure adherence to treatment and optimized outcomes. The aim of this review is to provide physicians with updated practical information for the prevention and management of AEs occurring during treatment with bosutinib, including dosing strategies, based on the latest published evidence and clinical experience. Clinical studies and real-world evidence have shown bosutinib has a generally favorable safety profile, which has remained consistent across lines of therapy and in long-term reports. Adjusting the starting dose and/or modifying the dose during treatment with bosutinib are important strategies to manage AEs and improve tolerability, which are recognized within the label and in treatment guidelines. Dosing adjustment strategies to manage AEs are a recognized management approach for other TKIs in the treatment of CML and are not exclusive to bosutinib. In summary, long-term results from clinical trials and emerging real-world evidence demonstrate bosutinib has a safety profile that can largely be managed with treatment modifications and/or supportive care. Increased experience in managing toxicities and by using a personalized dosing approach may further improve adherence and outcomes with bosutinib.

show abstract

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia

Lipton,

Brümmendorf,

Sweet

et al. 2024

Ann Hematol

View full text Add to dashboard Cite

show abstract

Bosutinib/dasatinib

2022

Reactions Weekly

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pulmonary Arterial Hypertension Worsened by Bosutinib in Patient With Previous Dasatinib Treatment

Cited by 2 publications

References 14 publications

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia

Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia

Bosutinib/dasatinib

Contact Info

Product

Resources

About